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Abstract
Background: The process of metastasis involves a series of steps and interactions between the tumor embolus and the
microenvironment. Key alterations in adhesion molecules are known to dictate progression from the invasive to malignant
phenotype followed by colonization at a distant site. The invasive phenotype results from the loss of expression of the E-
cadherin adhesion molecule, whereas the malignant phenotype is associated with an increased expression of the
carbohydrate ligand-binding epitopes, (e.g. Sialyl Lewis x/a) that bind endothelial E-selectin of the lymphatics and
vasculature.
Methodology: Our study analyzed the expression of two adhesion molecules, E-cadherin and Sialyl Lewis x (sLex), in both a
canine mammary carcinoma and human inflammatory breast cancer (IBC) model, using double labelled immunofluores-
cence staining.
Results: Our results demonstrate that canine mammary carcinoma and human IBC exhibit an inversely correlated cellular
expression of E-cadherin and sLex within the same tumor embolus.
Conclusions: Our results in these two comparative models (canine and human) suggest the existence of a biologically
coordinated mechanism of E-cadherin and sLex expression (i.e. molecular plasticity) essential for tumor establishment and
metastatic progression.
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Introduction
Metastasis is classically defined as the lymphatic or haematog-
enous (blood-born) dissemination of cancer cells from the primary
tumor (origin) to lymph nodes and/or to distant sites in the body
[1]. The process involves a complex series of steps and interactions
between the tumor cells and the microenvironment [2,3]. The
terminal step of this sequential process is colonization of the tumor
cells at distant sites in the body. The tendency of aggressive
cancers to metastasize is the cause of mortality from the disease
[4]. Determining the molecular mechanisms of metastasis is of the
utmost importance in an attempt to manage and treat cancer.
Although all cells of the tumor embolus arise from the same
parent cell, the embolus is composed of a heterogeneous
population of cells. Even in the most malignant primary tumor
not all cells have the capability of successfully colonizing at a
distant site [5]. This diversity, as well as the molecular and cellular
mechanisms underlying the metastatic potential of the tumor
embolus result from inherent (clonal selection) or acquired
(adaptive) traits or both of the tumor cells composing it [6,7].
Only a portion of those heterogeneous cells progress to the
malignant phenotype and even a smaller portion can successfully
colonize, and form deadly metastases [6]. The ability of those
tumor cells to conform to new environments is due to a molecular
plasticity. Among the events involved in molecular plasticity, loss
and gain of key adhesion molecules appears to be a significant
factor [8,9]. Key alterations in adhesion molecules are known to
dictate progression from the invasive to malignant phenotype
followed by colonization at a distant site [10].
E-cadherin and Sialyl Lewis x (sLex) are two adhesion molecules
that govern malignant progression. E-cadherin is an adhesion
molecule that plays a key role in homotypic cell-cell adhesion,
being classically considered a potent invasion/tumor suppressor
gene [9,11]. Furthermore, sLex antigen is a carbohydrate structure
that is involved in selectin-mediated adhesion of cancer cells to
vascular endothelium and this determinant is thought to be closely
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associated with haematogenous metastases of cancer [12,13]. sLex
not only is a marker for cancer but also is functionally implicated
in the malignant behaviour of cancer cells [14,15]. Overall, the
loss and gain of expression of these molecules are not aberrant
variations, but adaptive mechanisms of the cancer embolus, which
can defeat our present treatment modalities.
Naturally occurring cancers in canines and humans share many
features, including histological appearance, tumor genetics,
molecular targets, biological behaviour and response to conven-
tional therapies [16]. Mammary carcinomas, specifically, occur
among all taxonomic groups, and comparing the disease in canine
models with breast carcinoma in women could greatly improve
our understanding of the molecular biology underlying the process
of mammary tumorigenesis and progression [17].
In this report we demonstrate that canine mammary carcinoma
and the highly metastatic inflammatory breast cancer (IBC) in
women, exhibit an inversely correlated expression of E-cadherin
and sLex in cells of the same tumor embolus. Both mammary
carcinoma models support a coordinated expression between the
two adhesion molecules, suggesting a dynamic transition state or
molecular plasticity promoting tumor survival and dissemination
during the metastatic progression.
Materials and Methods
Ethics Statement
All experiments were performed in compliance with the
Memorial Sloan-Kettering Cancer Center Animal Care and Use
Program (Protocol Number 06-04-006).
MARY-X Xenograft and in vitro spheroids
MARY-X was established from a patient with inflammatory
breast cancer (IBC) [18]. In vivo, MARY-X recapitulates the
human IBC phenotype of extensive lymphovascular invasion of
the tumor cell emboli. The in vitro MARY-X spheroids are
prepared by mincing the extricated tumor followed by an
overnight incubation under standard tissue culture conditions.
The IBC cells are released as sheets and small spheroids initially.
Over a period of time, roughly 12–14 hours, the IBC cells as in
vivo, begin to overexpress E-cadherin and form tight, compact
spheroids in suspension. The compact, multicellular in cell
suspension spheroids are further purified by partitioning through
various size (100 mm, 70 mm and 40 mm pore size; BD
Biosciences) cell strainers to produce homogenous preparations
of spheroid sizes of 40 mm–70 mm, 70 mm–100 mm and 100+ mm
in diameter. Spheroids were maintained in minimal essential
medium (MEM) containing 10% fetal bovine serum and
antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) at
37uC in an air-5% CO2 atmosphere at constant humidity.
Canine mammary carcinoma cell line, CMT-U27
The canine mammary carcinoma cell line CMT-U27 was obtained
from the Uppsala University, Sweden. CMT-U27 cell line was derived
from a primary tumor (infiltrating ductal carcinoma) [19] and when
inoculated in the fat mammary pad of female nude mice metastasizes to
the lymph nodes, lungs, liver and heart. CMT-U27 was cultured in
RPMI 1640 with Glutamax medium (Gibco, Invitrogen), supplement-
ed with 10% fetal bovine serum (Gibco, Invitrogen) and 50 mg/ml
gentamicin (Gibco, Invitrogen). Culture was maintained at 37uC in a
humidified 5% CO2 atmosphere.
Tissue specimens
Ten tissue samples of primary canine mammary carcinomas of
different histological types (3 Complex carcinomas; 3 Tubulopa-
pillary carcinomas; 2 Carcinosarcoma; 2 Solid carcinomas) and 3
correspondent lung metastases were used in this study. Accord-
ingly with Peña L et al., canine inflammatory mammary
carcinoma (IMC) once diagnosed is involved with other histolog-
ical types of canine mammary carcinoma including solid
carcinomas, tubulopapillary carcinomas and sarcomatous type
[20]. The same is also true for feline IMC where the histology
revealed types of tubulopapillary mammary carcinomas [21]. In
addition, ten in vivo (primary tumor and metastases in SCID mice)
and ten in vitro specimens were harvested from the MARY-X
model. The specimens were fixed in 10% neutral buffered
formalin. After dehydration and paraffin wax embedment, 4 mm
thick sections were cut from each representative paraffin block for
staining with haematoxylin and eosin and for double-staining
immunofluorescence.
Double-Labelling Immunofluorescence
For simultaneous visualization of sLex and E-cadherin on the
same tissue section of the two comparative models, MARY-X and
canine mammary gland carcinomas, double-label immunofluores-
cence technique was performed.
Briefly, paraffin sections were dewaxed, rehydrated and then
treated with Extran (Merck, Frankfurt, Germany) 0.05% in
distilled water for 10 min in a microwave oven at 750 W. After
being left to cool for 20 min at room temperature, slides were
rinsed twice in Phosphate-buffered saline (PBS), and then
incubated for 20 min in a humid chamber with rabbit non-
immune serum at a dilution 1:5 in PBS containing 10% bovine
serum albumin (BSA). Sections were incubated with the first
primary monoclonal antibody (mAb), anti-human E-Cadherin
(clone 36, BD Biosciences Pharmingen, diluted 1:100 in PBS),
overnight at 4uC. After washing twice for 5 min in PBS, sections
were incubated with FITC-conjugated rabbit anti-mouse immu-
noglobulin (code F261; Dako, Glostrup, Denmark; diluted 1:100
in PBS). Sections were washed twice for 5 min in PBS and blocked
with non-immune goat serum diluted 1:5 in PBS containing BSA
10%. After incubation with mAb KM93 (mouse IgM) diluted at
1:40, overnight at 4uC, sections were washed twice for 5 min with
PBS and then incubated with Texas red-conjugated goat anti-
mouse IgM (Jackson Immunoresearch) diluted 1:50 in PBS.
Sections were washed as before and nuclei were counterstained
with 49-6-Diamidino-2-phenylindole (DAPI, Sigma) diluted at
1:100 in PBS, for 15 min in the dark. Finally, sections were
washed twice for 5 min in PBS and mounted with Vectashield
(Vector Laboratories, Burlingame, USA).
Dilutions of primary antibodies, secondary antibodies, and
DAPI were made with PBS containing 5% BSA.
Immunostained tissue sections were examined under a fluores-
cence microscope (Leica DMIRE2) equipped with appropriate
filters. Separate images for DAPI, Texas-Red and FITC staining
were captured digitally at X200 and X400 magnification. The red
(for Texas-Red), blue (for DAPI), and green (for FITC)
components were merged and combined images were imported
into Adobe PhotoshopH.
Immunoprecipitation of E-cadherin from CMT-U27
Cells from CMT-U27 cell line were washed with cold
phosphate-buffered saline (PBS) and then lysed with a lysis buffer
(1% (v/v) Triton X-100; 1% (v/v) NP-40 in PBS, containing
protease inhibitor cocktail (Roche), 100 mM Na3VO4, 100 mM
PMSF) for 15 min on ice. After scraping cell monolayers with a
rubber policeman the suspension was centrifuged at 14000 rpm for
10 min at 4uC. Protein concentrations were determined by using a
BCA protein assay kit (Pierce).
Molecular Plasticity
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Total protein (750 mg) of canine cell line was precleared with
50 ml of protein G-sepharose beads (Sigma Aldrich) at 4uC under
agitation for 1–2 h to remove non-specific adsorption to the
sepharose beads.
After centrifugation at 14000 rpm for 5 min at 4uC, supernatant
was incubated overnight at 4uC under agitation with 5 mg of
monoclonal antibody against E-cadherin (monoclonal mouse anti
human E-cadherin, clone 36, BD Biosciences Pharmingen). Then,
incubation with protein G-sepharose at 4uC for 2 h with agitation
was performed. Next, the beads were washed three times with an
immunoprecipitation buffer (10% (v/v) lysis buffer, 5 mg/ml
Na4P2O7, 1% (v/v) NaF 100X in PBS). The immune complexes
were released by boiling 5 min at 95uC in Laemmli sampling
buffer prior to analyses by Western.
For sLex carbohydrate detection of E-cadherin immunoprecip-
itated, nitrocellulose membrane was blocked and then incubated
with monoclonal antibody that specifically recognizes sLex epitope
(KM93) with a dilution of 1 mg/ml in PBS with 0.01% Tween 20
(PBS T) with 5% milk.
The membrane was washed three times with PBS T and
incubated with HRP-conjugated anti-mouse IgM secondary
antibody (Santa Cruz Biotechnology, 1:3000 diluted in PBS T
with 5% milk) during 1 h at room temperature. After washing
three times with PBS T, membrane was developed by an ECL
according to the manufacturer’s recommended protocol.
Results
Inversely correlated cellular expression of E-cadherin and
sLex in the MARY-X spheroid
MARY-X, like IBC, grows exclusively within the murine lymphatics
and blood vessels, which is the signature phenotype of this highly
aggressive, malignant breast carcinoma [18]. Both the MARY-X in
vitro spheroid (Figure 1A) and in vivo tumor embolus [data not shown]
form on the basis of an intact, over-expressed E-cadherin/a,b catenin
axis [22]. Interestingly, MARY-X displays a unique relationship of two
key adhesion molecules; over-expression of E-cadherin and under-
expression of sLex confirmed by western blot analysis [23,24]. This
relationship is contrary to what would be expected in a highly
malignant carcinoma. To determine if expression levels were due to a
homogenous population of cellular expression (i.e. each cell produced
excessive amounts of E-cadherin and a limited amount of sLex) double-
labeling immunofluorescence of the two adhesion molecules was
performed. The majority of cells of the MARY-X in vitro spheroid
displayed membrane-positioned E-cadherin (green) expression only
(Figure 1B). A minority population co-expresses both molecules with a
cytoplasmic-positioned sLex (red) expression (Figure 1C and 1D). An
even smaller population of cells, of the MARY-X in vitro spheroid
display membrane-positioned sLex (red) expression only (Figure 1D).
Co-expression of these two adhesion molecules is rarely seen. Hence
the MARY-X spheroid displays an inverse relationship of expression of
E-cadherin and sLex. Previous studies indicated a cooperative
relationship between E-cadherin and sLex [23]. However, our study
shows that the expression levels are not due to a homogenous
population of cellular expression but rather a heterogeneous population
of cellular expression. A similar inversely correlated cellular expression
between these two key adhesion molecules has also been reported in a
malignant canine mammary carcinoma model and was the basis of this
study [25].
Inversely correlated cellular expression of E-cadherin and
sLex throughout the metastatic progression of MARY-X
and canine mammary carcinoma
Since adhesion molecules dictate metastatic progression of
carcinomas, double labeling immunofluorescence of E-cadherin
and sLex was performed on the primary tumor and corresponding
metastases of both the MARY-X and canine mammary carcinoma
models to determine the presence of a correlated cellular
expression throughout metastatic progression. The majority of
the cell population of the primary tumor of both the MARY-X
and canine models display a strong membrane-positioned E-
cadherin (green) expressing cells with no expression of sLex
(Figure 2A & 2B). To a lesser extent, nests of sLex (red) expressing
cells could be seen throughout both models (Figure 2A & 2B). In
the MARY-X model, as seen in vitro, sLex is cytoplasmic-positioned
and co-expressed with membrane-positioned E-cadherin
(Figure 2A; middle panel). However, a small number of cells
display membrane-positioned sLex expression only (Figure 2A;
middle panel). The canine primary tumor is very comparable to
MARY-X except that the nests of sLex expressing cells
predominantly display membrane- positioned sLex only, i.e. no
co-expression of the two molecules (Figure 2B; middle panel). The
corresponding metastasis of MARY-X and the canine mammary
carcinoma also show a dominant population of cells expressing
Figure 1. Expression of E-cadherin and sLex in the MARY-X spheroid. (A) MARY-X in vitro spheroid forms a compact, clump of cells due to
over-expression of a key adhesion molecule, E-cadherin (light microscopy; 406magnification). (B) Illustrates a heterogeneous population of cellular
expression with a dominant population of cells expressing membrane-positioned E-cadherin (green) and a minority population of cells expressing
sLex (red). (C & D) sLex was found to be either cytoplasmic- (long arrows) or membrane-positioned (blunt arrows).
doi:10.1371/journal.pone.0006636.g001
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Figure 2. Expression of E-cadherin and sLex throughout the metastatic progression of MARY-X and canine mammary carcinoma. (A,
B) Shows a heterogeneous population of cellular expression in both (A) MARY-X primary tumors and (B) canine primary tumors (carcinosarcoma and
solid carcinoma) displaying a dominant population of cells with membrane-positioned E-cadherin (green) and smaller nests sLex (red) expressing cells
(cytoplasmic or membrane-positioned). (A, B; middle panels) Magnified image shows the sLex found either cytoplasmic- (long arrows) or
membrane-positioned (blunt arrows). Mary-X lung metastasis (MARY-X metastasis) displays a dominant population of cells expressing only E-
cadherin (green), and a minority population of cells co-expressing cytoplasmic-positioned sLex (red) (long arrows). (B, C) Canine lung metastasis
(Canine metastasis) displays a dominant population of cells expressing only E-cadherin (green), and minority populations of cells either co-
expressing cytoplasmic-positioned sLex (red) (long arrows) or expressing only membrane-positioned sLex (red) (blunt arrows).
doi:10.1371/journal.pone.0006636.g002
Molecular Plasticity
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6636
only membrane-positioned E-cadherin (green) (Figure 2A & 2B;
right panel and Figure 2C). However, in the few sLex expressing
cells of the MARY-X metastasis co-expression of membrane-
positioned E-cadherin with cytoplasmic-positioned sLex was seen
(Figure 2A; right panel). The canine metastasis showed predom-
inantly membrane-positioned sLex expressing only cells (Figure 2B;
right panel and Figure 2C). In the primary tumor and
corresponding metastases of both models, co-expression is a rare
event. Therefore both models maintain a heterogeneous popula-
tion of cellular expression through out the metastatic progression
displaying an inversely correlated cellular expression of these two
key adhesion molecules.
Sialyl-Lewis X does not mask E-cadherin expression
An E-cadherin immunoprecipitation (IP) was performed in
order to rule out the possibility that sLex immunofluorescense (red)
masked E-cadherin immunofluorescense (green) in cells that
displayed sLex expression only (i.e. E-cadherin is a carrier of
sLex). This approach was only performed on the canine model due
to the greater number of cells that express only sLex as compared
to the MARY-X model. The evaluation of the expression of sLex
using a specific monoclonal antibody showed no detection of this
carbohydrate antigen on the E-cadherin immunoprecipitate from
canine mammary carcinoma cell line, CMT-U27 (Figure 3). This
finding excludes the possibility that the sLex carbohydrate is
attached to E-cadherin.
Discussion
zTumor cell formation and development of metastasis is a
multistep process involving complex interactions between cancer
cells, extracellular matrix, lymphovascular system, immune system
and target organs [4]. The loss (e.g. E-cadherin) and gain (e.g.
carbohydrate ligand-binding epitopes) of key adhesion molecules
are contributing factors in the metastatic process [11,12]. This
study investigated two interesting exceptions to the above rule,
namely the inflammatory breast cancer model, MARY-X and a
canine mammary carcinoma model. Both models are highly
metastatic, yet display neither a loss in E-cadherin expression nor
overall gain in the carbohydrate ligand-binding epitope of
endothelial cells, sLex [25,26]. Rather, these two exceptions
suggest a more ‘‘adaptable’’ metastatic progression as opposed to a
‘‘one way’’ progression from the invasive (loss of E-cadherin
expression) to malignant phenotype (gain in sLex expression). The
heterogeneous population of cellular expression suggests a
dynamic ‘‘back and forth’’ transition state between phenotypes
that might promote survival of the tumor embolus during
metastatic progression.
Our study shows a correlated inverse relationship of E-cadherin
and sLex expression in the genesis, dissemination and subsequent
metastases in the MARY-X and canine mammary carcinoma
models. These preliminary findings suggest that loss and gain in
expression of adhesion molecules is not an aberrant variation but
rather an adaptive cellular and molecular mechanism of the
cancer that contribute to its metastatic ability. Our findings are the
beginning to a better understanding of these adaptive mechanisms.
More specifically, since molecular variation contributes to cancer
progression and survival then the present findings set the ground
for targeting these mechanisms resulting in new therapeutic
strategies of metastatic disease. Further work is in progress
regarding the clarification of the molecular mechanism underlying
gene expression of these two key molecules through out the
metastatic progression in both comparative models.
In conclusion, our study suggests the existence of a biologically
coordinated mechanism of E-cadherin and sLex expression (i.e.
molecular plasticity) essential for tumor establishment and
metastatic progression.
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